FDA to consider approval of new class of cholesterol drugs
PCSK9 inhibitors are self-injected every 2 weeks, and work by blocking substance that hinders liver's ability to remove cholesterol from blood
Washington
A FEDERAL advisory committee this week will decide whether to recommend approval of the first in a new class of drugs that many experts believe could significantly cut the risk of strokes and heart attacks, a leading cause of death for Americans.
The highly anticipated new drugs have been shown in clinical trials to sharply reduce levels of bad, or LDL cholesterol, representing the first major advance in the area since widely used statin drugs hit the market in the late 1980s.
"This is one of the biggest developments in a long time in cardiology," …
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Cordlife customers push for legal action
China knockoff raid jolts a global throng of fake-fashion influencers
Apparel company Express seeks quick bankruptcy sale
Mattel posts narrower loss, thanks to Hot Wheels growth and lower costs
Starbucks set for talks with unionised US stores
Gucci-owner Kering posts 10% drop in Q1 sales on sluggish Chinese demand